title: Decision on folic acid fortification in Europe must consider both risks and benefits.
authors.affiliation: Department of Pharmacology, University of Oxford, Oxford, UK david.smith@pharm.ox.ac.uk.
authors.forename: A David
authors.initials: AD
authors.lastname: Smith
authors.affiliation: Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
authors.forename: Helga
authors.initials: H
authors.lastname: Refsum
authors.affiliation: Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Selhub
authors.affiliation: Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.
authors.forename: Irwin H
authors.initials: IH
authors.lastname: Rosenberg
mesh_terms: D019587:Dietary Supplements / Q000706:statistics & numerical data*; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D009436:Neural Tube Defects; D011247:Pregnancy; D011248:Pregnancy Complications
chemical_list: D005492:Folic Acid